Related Experiment Video

Updated: May 11, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

[Oral antidiabetic drugs. How to begin and combine without cardiovascular risk]

Rui Duarte1

  • 1Médico Diabetologista da APDP, Lisbon, Portugal. ruisduarte@mail.telepac.pt

Revista Portuguesa De Cardiologia : Orgao Oficial Da Sociedade Portuguesa De Cardiologia = Portuguese Journal of Cardiology : an Official Journal of the Portuguese Society of Cardiology
|June 1, 2013
PubMed

Insights

Type 2 diabetes poses significant cardiovascular risks. New hyperglycemia drugs require cardiovascular safety data due to past drug concerns, making safe treatment a key concern.

Area of Science:

  • Endocrinology and Metabolism
  • Cardiovascular Medicine
  • Pharmacology

Context:

  • Diabetes mellitus is a major risk factor for cardiovascular disease (CVD), which is the leading cause of mortality in diabetic patients.
  • Recent trials show glycemic control in type 2 diabetes does not consistently reduce cardiovascular events and may increase mortality.
  • Concerns about cardiovascular safety have led to restrictions on drugs like rosiglitazone, highlighting the need for safer treatments.

Purpose:

  • To address the critical need for cardiovascularly safe treatments for hyperglycemia in type 2 diabetes.
  • To emphasize the regulatory requirement for pre-clinical cardiovascular safety data for new antidiabetic drugs.
  • To underscore the ongoing challenge of managing type 2 diabetes while minimizing cardiovascular risk.

Summary:

  • Randomized controlled trials have yielded inconclusive results regarding the cardiovascular benefits of glycemic control in type 2 diabetes.
  • A meta-analysis revealed increased ischemic cardiovascular events associated with rosiglitazone, leading to regulatory actions.
  • Current regulatory standards mandate rigorous cardiovascular safety assessments for all new hyperglycemia medications.

Impact:

  • This highlights the urgent necessity for developing and approving antihyperglycemic agents with proven cardiovascular safety.
  • Ensures that new diabetes medications prioritize patient well-being by mitigating cardiovascular risks.
  • Advances the field of diabetes management by focusing on a dual approach of efficacy and safety.

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...